The Danish drugmaker Novo Nordisk has officially launched its weight loss pill, Wegovy, in the United States as of March 15, 2024. The medication, which is...
Health Canada is currently reviewing nine submissions for generic versions of popular obesity medications, potentially paving the way for lower prices this summer. The focus is...
The oral medication Wegovy, designed for weight loss in adults, may soon be available in Canada pending approval from Health Canada. This announcement follows the recent...
Negotiations to include the weight-loss drug Wegovy under Canadian public health plans have collapsed as Novo Nordisk, the Danish manufacturer, declined to pursue discussions. This development...
Novo Nordisk has announced significant price reductions for its obesity treatments, Wegovy and Ozempic, in an effort to compete more effectively against rival Eli Lilly, which...
Novo Nordisk has announced a significant price reduction for its weight-loss injection, Wegovy, by up to 37% in India. This strategic decision comes as the Danish...
Shares in Novo Nordisk dropped by as much as 3 percent on Friday following a pricing agreement between the Danish pharmaceutical company and its U.S. competitor...
Novo Nordisk A/S has revised its 2025 sales forecast for the fourth time in 2023, attributing the adjustment to weaker-than-anticipated demand for its leading medications, Wegovy...
